— Know what they know.
Not Investment Advice

BLTE NASDAQ

Belite Bio, Inc
1W: -2.7% 1M: -14.3% 3M: -8.1% YTD: -10.0% 1Y: +55.4% 3Y: +343.1%
$145.72
+2.37 (+1.65%)
After Hours: $148.58 (+2.86, +1.96%)
Weekly Expected Move ±6.0%
$130 $138 $147 $156 $165
NASDAQ · Healthcare · Biotechnology · Tech Score Strong Sell · Power 25 · $5.8B mcap · 20M float · 0.960% daily turnover · Short 64% of daily vol
Credit Risk of going bust: not rated Debt: 0.0% of company value Bonds: none of note held by US funds details ▾
Not rated: no debt. Altman Z'' 57.62.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.

Cash Flow Trends

Operating Cash Flow
-$29M +2.0% ▲
Capital Expenditures
$151K -139.7% ▼
4Y CAGR: +65.8%
Free Cash Flow
-$29M +1.7% ▲
Dividends Paid
$0 +0.0% ▲
Buybacks
$0 +0.0% ▲
Net Change in Cash
-$56M -222.6% ▼

Cash Flow Composition

Year-over-Year Growth

View Full Cash Flow Statement
Line ItemFY2020FY2021FY2022FY2023FY2024
— Operating Activities —
Net Income-$6M-$10M-$13M-$32M-$36M
Depreciation & Amort.$17K$30K$198K$399K$449K
Stock-Based Comp.$1M$2M$1M$4M$9M
Change in Working Capital-$69K$640K-$491K-$2M$1M
Other Non-Cash Items$1M-$8K$2M$5M-$4M
Operating Cash Flow-$4M-$7M-$11M-$30M-$29M
— Investing Activities —
Capital Expenditures-$20K-$74K-$394K-$63K-$116K
Acquisitions (Net)$0$18K$0$0$0
Investment Purchases$0$0$0$0-$188M
Investment Sales$0$0$0$0$78M
Other Investing$0$0$0$0-$35K
Investing Cash Flow-$20K-$56K-$394K-$63K-$111M
— Financing Activities —
Net Debt Issuance-$2M$0$0$0$0
Stock Repurchased$0$0$0$0$0
Dividends Paid$0$0$0$0$0
Other Financing$86K$0-$1M-$1M$41M
Financing Cash Flow$28M-$583K$37M$76M$84M
Net Change in Cash$24M-$8M$25M$46M-$56M
Cash End of Period$26M$17M$42M$88M$32M
Free Cash Flow-$4M-$8M-$12M-$30M-$29M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms